Home / Business and Economy / AngioDynamics: MedTech Poised for Revenue Dominance by 2027
AngioDynamics: MedTech Poised for Revenue Dominance by 2027
12 Aug
Summary
- MedTech revenue grew 19% in fiscal '26, reaching 47% of total.
- Auryon platform generated $68 million in fiscal '26 revenue.
- Company aims for MedTech to be majority revenue by fiscal '27.
AngioDynamics is undergoing a significant transformation, with its MedTech business anticipated to become the primary revenue generator by fiscal year 2027. This strategic pivot moves the company away from slower-growth legacy markets towards higher-potential medical technology platforms.
MedTech accounted for 47% of AngioDynamics' revenue in fiscal year 2026, a substantial increase from approximately 17% when the transformation began. The segment experienced 19% growth in the most recent fiscal year, marking seven consecutive quarters of double-digit expansion.
Key growth drivers within MedTech include the Auryon peripheral artery disease platform, mechanical thrombectomy devices, and the NanoKnife oncology system. Auryon, acquired five years prior, generated about $68 million in revenue in fiscal year 2026 and is expected to grow at a robust pace.
The company is also exploring future opportunities, including a potential coronary application for Auryon, which would likely involve a multi-year study and regulatory approval process with the U.S. Food and Drug Administration.
